טוען...
Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment
BACKGROUND: Tenofovir (TDF) is considered as the first line therapy for chronic hepatitis B. This study presents the results of TDF monotherapy in patients who failed previous nucleoside analogue treatment. METHODS: The study included 29 patients treated with TDF 245 mg once daily for 18 months afte...
שמור ב:
| הוצא לאור ב: | Hepatol Int |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer India
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4778152/ https://ncbi.nlm.nih.gov/pubmed/26612013 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12072-015-9681-6 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|